One of the spillover effects of the COVID-19 pandemic has been the increase in opioid-related deaths. These deaths overwhelmingly affect working-class Americans with limited access and resources to lifesaving drugs such as...more
6/10/2021
/ Biden Administration ,
Certification Requirements ,
DEA ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Medicare ,
Notice of Intent ,
Opioid ,
Prescription Drugs ,
SAMHSA
The Food and Drug Administration (FDA) and the National Telecommunications Information Administration (NTIA) in partnership with three domain name registries disabled nearly 30 websites illegally offering opioids for sale....more
2/11/2021
/ DEA ,
Department of Health and Human Services (HHS) ,
Domain Name Registration ,
Enforcement Actions ,
FDA Warning Letters ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Federal Pilot Programs ,
Food and Drug Administration (FDA) ,
NTIA ,
Opioid ,
Prescription Drugs
It has been a long time coming. On November 2, 2020, the Drug Enforcement Administration (DEA) released its long-awaited proposed rule to revise the regulations related to suspicious orders of controlled substances. The...more
11/9/2020
/ Controlled Substances ,
Controlled Substances Act ,
DEA ,
Due Diligence ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Rules ,
Recordkeeping Requirements ,
Substance Abuse ,
Wholesale
We’ve previously blogged about the regulation of CBD by the Food and Drug Administration (FDA), and it appears that the dialogue around CBD isn’t slowing down as we continue through the second half of 2019. Recently, a...more
8/21/2019
/ Cannabidiol (CBD) oil ,
DEA ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Health and Safety ,
Investigational New Drug Application (IND) ,
Marijuana ,
Marijuana Related Businesses ,
Marijuana-Infused Edibles ,
Proposed Legislation ,
Regulatory Agenda ,
Regulatory Oversight ,
Schedule I Drugs